<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: following risks actually", fill: "#fff700"},
{source: "4: following risks actually", target: "4: financial condition", fill: "#fff700"},
{source: "4: financial condition", target: "4: operations would likely suffer", fill: "#fff700"},
{source: "4: following risks actually", target: "5: market price", fill: "#6da"},
{source: "5: market price", target: "5: common stock could fall", fill: "#6da"},
{source: "5: common stock could fall", target: "5: buy such common stock", fill: "#6da"},
{source: "5: market price", target: "7: risks associated with purchasing", fill: "#039"},
{source: "7: risks associated with purchasing", target: "7: commons stock", fill: "#039"},
{source: "7: commons stock", target: "7: investment", fill: "#039"},
{source: "7: risks associated with purchasing", target: "8: transaction", fill: "#fb9902"},
{source: "8: transaction", target: "8: current ownership position", fill: "#fb9902"},
{source: "8: current ownership position", target: "8: preferred stock persons", fill: "#fb9902"},
{source: "8: preferred stock persons", target: "8: common stock", fill: "#fb9902"},
{source: "8: common stock", target: "8: exercise voting control over most", fill: "#fb9902"},
{source: "8: exercise voting control over most", target: "8: matters put", fill: "#fb9902"},
{source: "8: matters put", target: "8: stockholders", fill: "#fb9902"},
{source: "8: transaction", target: "19: fund may pursue", fill: "#ffa343"},
{source: "19: fund may pursue", target: "19: acquisition", fill: "#ffa343"},
{source: "19: acquisition", target: "19: account acquisition opportunities", fill: "#ffa343"},
{source: "19: account acquisition opportunities", target: "19: complementary", fill: "#ffa343"},
{source: "19: complementary", target: "19: opportunities may", fill: "#ffa343"},
{source: "19: fund may pursue", target: "24: capital requirements will depend on", fill: "#b7410e"},
{source: "24: capital requirements will depend on", target: "24: PHD Systems ", fill: "#b7410e"},
{source: "24: PHD Systems ", target: "24: manufacturing", fill: "#b7410e"},
{source: "24: manufacturing", target: "24: distribution", fill: "#b7410e"},
{source: "24: distribution", target: "24: development", fill: "#b7410e"},
{source: "24: development", target: "24: proprietary", fill: "#b7410e"},
{source: "24: capital requirements will depend on", target: "25: operations", fill: "#f1a7fe"},
{source: "25: operations", target: "25: PHD Systems ", fill: "#f1a7fe"},
{source: "25: operations", target: "37: capital constraints may", fill: "#007ba7"},
{source: "37: capital constraints may", target: "37: difficult", fill: "#007ba7"},
{source: "37: difficult", target: "37: PHD System ", fill: "#007ba7"},
{source: "37: capital constraints may", target: "START_HERE", fill: "#007ba7"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Oil and Gas Exploration and Production</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price">Price</a></td>
      <td>A prince is a male ruler (ranked below a king, grand prince, and grand duke) or a male member of a monarch's or former monarch's family. Prince is also a title of nobility (often highest), often hereditary, in some European states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_trend">Market trend</a></td>
      <td>A market trend is a perceived tendency of financial markets to move in a particular direction over time. These trends are classified as secular for long time frames, primary for medium time frames, and secondary for short time frames.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_power">Market power</a></td>
      <td>In economics, market power refers to the ability of a firm to influence the price at which it sells a product or service by manipulating either the supply or demand of the product or service to increase economic profit. In other words, market power occurs if a firm does not face a perfectly elastic demand curve and can set its price (P) above marginal cost (MC) without losing revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing">Pricing</a></td>
      <td>Pricing is the process whereby a business sets the price at which it will sell its products and services, and may be part of the business's marketing plan. In setting prices, the business will take into account the price at which it could acquire the goods, the manufacturing cost, the marketplace, competition, market condition, brand, and quality of product.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-price_competition">Non-price competition</a></td>
      <td>Non-price competition is a marketing strategy "in which one firm tries to distinguish its product or service from competing products on the basis of attributes like design and workmanship". It often occurs in imperfectly competitive markets because it exists between two or more producers that sell goods and services at the same prices but compete to increase their respective market shares through non-price measures such as marketing schemes and greater quality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_structure">Market structure</a></td>
      <td>Market structure, in economics, depicts how firms are differentiated and categorised based on the types of goods they sell (homogeneous/heterogeneous) and how their operations are affected by external factors and elements. Market structure makes it easier to understand the characteristics of diverse markets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Annual_general_meeting">Annual general meeting</a></td>
      <td>An annual general meeting (AGM, also known as the annual meeting) is a meeting of the general membership of an organization.\nThese organizations include membership associations and companies with shareholders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholders'_agreement">Shareholders' agreement</a></td>
      <td>A shareholders' agreement (sometimes referred to in the U.S. as a stockholders' agreement) (SHA) is an agreement amongst the shareholders or members of a company. In practical effect, it is analogous to a partnership agreement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Friedman_doctrine">Friedman doctrine</a></td>
      <td>The Friedman doctrine, also called shareholder theory or stockholder theory, is a normative theory of business ethics advanced by economist Milton Friedman which holds that the social responsibility of business is to increase its profits. This shareholder primacy approach views shareholders as the economic engine of the organization and the only group to which the firm is socially responsible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second-language_acquisition">Second-language acquisition</a></td>
      <td>Second-language acquisition (SLA), sometimes called second-language learning — otherwise referred to as L2 (language 2) acquisition, is the process by which people learn a second language. Second-language acquisition is also the scientific discipline devoted to studying that process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Doctor_of_Philosophy">Doctor of Philosophy</a></td>
      <td>A Doctor of Philosophy (PhD, Ph.D., or DPhil; Latin: philosophiae doctor or doctor philosophiae) is the most common degree at the highest academic level awarded following a course of study. PhDs are awarded for programs across the whole breadth of academic fields.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Solar_System">Solar System</a></td>
      <td>A star system or stellar system is a small number of stars that orbit each other, bound by gravitational attraction. A large group of stars bound by gravitation is generally called a star cluster or galaxy, although, broadly speaking, they are also star systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Geographic_information_system">Geographic information system</a></td>
      <td>A geographic information system (GIS) is a type of database containing geographic data (that is, descriptions of phenomena for which location is relevant), combined with software tools for managing, analyzing, and visualizing those data. In a broader sense, one may consider such a system to also include human users and support staff, procedures and workflows,  body of knowledge of relevant concepts and methods, and institutional organizations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Type_system">Type system</a></td>
      <td>In programming languages, a type system is a logical system comprising a set of rules that assigns a property called a type to the various constructs of a computer program, such as variables, expressions, functions or modules. These types formalize and enforce the otherwise implicit categories the programmer uses for algebraic data types, data structures, or other components (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Condor">Operation Condor</a></td>
      <td>Operation Condor (Spanish: Operación Cóndor, also known as Plan Cóndor; Portuguese: Operação Condor) was a United States-backed campaign of political repression and state terror involving intelligence operations and assassination of opponents. It was officially and formally implemented in November 1975 by the right-wing dictatorships of the Southern Cone of South America.Due to its clandestine nature, the precise number of deaths directly attributable to Operation Condor is highly disputed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Difficult_Woman">A Difficult Woman</a></td>
      <td>A Difficult Woman is an Australian television series which screened in 1998 on the ABC. The three part series starred Caroline Goodall, in the title role of a woman whose best friend is murdered and is determined to find out why. It was written by Nicholas Hammond and Steven Vidler and directed by Tony Tilse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_to_Cure">Difficult to Cure</a></td>
      <td>Difficult to Cure is the fifth studio album by the British hard rock band Rainbow, released in 1981. The album marked the further commercialization of the band's sound, with Ritchie Blackmore once describing at the time his appreciation of the band Foreigner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/For_Love_or_Money_(2014_film)">For Love or Money (2014 film)</a></td>
      <td>For Love or Money (Chinese: 露水红颜) is a Chinese romance film based on Hong Kong novelist Amy Cheung's 2006 novel of the same name. The film was directed by Gao Xixi and starring Liu Yifei and Rain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Difficult_Couple">The Difficult Couple</a></td>
      <td>The Difficult Couple (Chinese: 难夫难妻; pinyin: Nànfū Nànqī), also translated as Die for Marriage, is a 1913 Chinese film. It is known for being the earliest Chinese feature film.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_(song)">Difficult (song)</a></td>
      <td>"Difficult" is the fourth single from French-American recording artist Uffie's debut album, Sex Dreams and Denim Jeans. The single was produced by Uffie's label-mate and friend SebastiAn and was released by Ed Banger Records, Because Music and Elektra Records on October 18, 2010.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AKSYS LTD      Item 1A                <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>You should     <font color="blue">carefully</font>  consider the risks and <font color="blue"><font color="blue">uncertainties</font> described</font> below before     investing</td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occur, our business,     <font color="blue">financial condition</font>, or results of <font color="blue"><font color="blue">operations</font> <font color="blue">would likely</font> suffer</font></td>
    </tr>
    <tr>
      <td>In that     case, the <font color="blue">market price</font> of the <font color="blue"><font color="blue">common stock</font> could fall</font>, and you may lose all     or  part of the money you paid to <font color="blue">buy such <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>Also consider     <font color="blue">carefully</font>  the  statements  under the heading “Note on Forward-Looking     Information” below</td>
    </tr>
    <tr>
      <td>You should be prepared to accept the occurrence of any     and all of the <font color="blue">risks <font color="blue">associated with</font> purchasing</font> our <font color="blue">commons stock</font>, including     a loss of all of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       As a result of our <font color="blue">transaction</font> with <font color="blue">the Durus </font>fund and <font color="blue">the Durus </font>fund’s     <font color="blue">current ownership position</font> in our common and <font color="blue">preferred stock</font>, persons other     than <font color="blue">the Durus </font>fund who own our <font color="blue">common stock</font> will own a minority of our     <font color="blue">common stock</font> and will not be able to <font color="blue">exercise <font color="blue">voting control</font> over most</font>     <font color="blue">matters put</font> to a vote of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>On  March 31,  2006  we executed <font color="blue">definitive <font color="blue">agreement</font>s</font> for a financing     <font color="blue">transaction</font> with <font color="blue">the Durus </font>fund</td>
    </tr>
    <tr>
      <td>These <font color="blue">documents</font> included an <font color="blue">amendment</font> to     our <font color="blue">existing settlement <font color="blue">agreement</font> with</font> <font color="blue">the Durus </font>fund and Artal Long Biotech     Portfolio LLC (the “Artal fund”) to release <font color="blue">the Durus </font>fund and the <font color="blue">Artal     </font><font color="blue">fund from standstill</font> and other <font color="blue">restrictive covenants</font>, including <font color="blue">elimination</font>     of the <font color="blue">requirement</font> for <font color="blue">the Durus </font>fund to reduce its ownership in our common     stock to 15prca by May 2006 and the <font color="blue">requirement</font> that, on matters requiring the     vote of the Company’s <font color="blue">stockholders</font>, <font color="blue">the Durus </font>fund and the Artal fund vote     their shares of the Company’s <font color="blue">common stock</font> in proportion to the votes cast     by all other holders of the Company’s <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>By releasing <font color="blue">the Durus </font>    fund from these <font color="blue">restrictions</font>, <font color="blue">the Durus </font>fund is <font color="blue">no longer prohibited from</font>     acquiring our securities or making any <font color="blue">solicitation</font> of proxies to vote our     shares</td>
    </tr>
    <tr>
      <td>In  addition, we took actions to amend our <font color="blue">shareholder rights</font>     <font color="blue">agreement</font>  so  that it will not be applicable to <font color="blue">the Durus </font>fund or the     <font color="blue">transaction</font>s with <font color="blue">the Durus </font>fund and to eliminate our <font color="blue">shareholder rights</font>     <font color="blue">outstanding under</font> our rights <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Stockholders </font>other than <font color="blue">the Durus </font>fund own a minority of our outstanding     shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>After giving effect to the financing <font color="blue">transaction</font>,     <font color="blue">the Durus </font>fund’s ownership position and <font color="blue">representation on</font> the board of     <font color="blue">directors</font> will entitle <font color="blue">the Durus </font>fund to <font color="blue">exercise control over most matters</font>     put to a vote of our board of <font color="blue">directors</font> and our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Durus </font>fund     will be in a position to control the election of our <font color="blue">directors</font>, determine     our corporate and <font color="blue"><font color="blue">management</font> policies</font> and to determine, without the consent     of our other <font color="blue">stockholders</font>, the outcome of any corporate <font color="blue">transaction</font> or other     matter submitted to our <font color="blue">stockholders</font> for approval, including exercising its     <font color="blue">voting control</font> to prevent a sale or merger <font color="blue">transaction</font> in which <font color="blue">stockholders</font>     could receive a premium for their shares</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Durus </font>fund also     has <font color="blue">sufficient voting power</font> to amend our organizational <font color="blue">documents</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Durus </font>fund’s interests may not <font color="blue">coincide with</font> the interests of other     holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Durus </font>fund is in the business of making     <font color="blue">investment</font>s  in companies and may, from time to time, acquire and hold     interests in <font color="blue">businesses</font> that <font color="blue">compete directly</font> or <font color="blue">indirectly with us</font></td>
    </tr>
    <tr>
      <td>The     Durus <font color="blue">fund may pursue</font>, for its own account, <font color="blue">acquisition</font> <font color="blue">opportunities</font> that     may be <font color="blue">complementary</font> to our business, and as a result, those <font color="blue">acquisition</font>     <font color="blue"><font color="blue">opportunities</font> may</font> not be available to us</td>
    </tr>
    <tr>
      <td>Such <font color="blue">concentration</font> of ownership     <font color="blue">could also</font> have the effect of delaying, deterring or preventing a change in     control  of the Company that <font color="blue">might otherwise</font> be <font color="blue">beneficial</font> to minority     <font color="blue">stockholders</font> and may also discourage <font color="blue">acquisition</font> bids for the Company and     limit the amount certain investors may be willing to pay for shares of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       We  require  <font color="blue">additional</font>  capital to operate our business which, if not     available to us, may prevent our ability to <font color="blue">continue <font color="blue">operations</font></font> and which,     if raised, will dilute stockholder ownership interest in us or otherwise     reduce the value of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our capital <font color="blue">requirement</font>s have been and <font color="blue">will continue</font> to be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>To     date, we have raised <font color="blue">approximately</font> dlra152 million from equity offerings and     have received <font color="blue">approximately</font> dlra53dtta7 million in payments and <font color="blue">financings from</font>     the  Durus  fund,  <font color="blue">approximately</font> dlra48dtta7 million as part of the original     settlement in 2004 and dlra5dtta0 million on March 31, 2006 in the form of a short     term loan</td>
    </tr>
    <tr>
      <td>Our capital <font color="blue">requirement</font>s will depend on many factors, including     without limitation:       ·       the cost of servicing and supporting <font color="blue">PHD Systems </font>in use;       ·       <font color="blue">manufacturing</font> and associated costs;       ·       costs <font color="blue">associated with</font> marketing, <font color="blue">distribution</font>, patient training and     technical and patient <font color="blue">support networks</font>;       ·       continued progress in research and <font color="blue">development</font>; and       ·       the costs involved with protecting our <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>During  2006, we expect to use <font color="blue">approximately</font> dlra16 to dlra18 million in our     <font color="blue">operations</font> including service and support of the <font color="blue">PHD Systems </font>being used by     patients  today</td>
    </tr>
    <tr>
      <td><font color="blue">Resources </font>will also be <font color="blue">directed toward using</font> the PHD     System’s <font color="blue">platform technology</font> to develop our <font color="blue">next generation product</font></td>
    </tr>
    <tr>
      <td>We     believe our cash and liquid <font color="blue">investment</font>s (including the receivable for the     settlement of the sale of long-term <font color="blue">investment</font> securities) at <font color="blue">December </font>31,     2005, combined with expected <font color="blue">proceeds from</font> <font color="blue">the Durus </font><font color="blue">fund financing</font>, are     <font color="blue">only sufficient</font> to finance our <font color="blue">operations</font> into 2007</td>
    </tr>
    <tr>
      <td>In 2006, we will seek     to raise the <font color="blue">additional</font> capital required to <font color="blue">fund commercial activities</font> in     2007</td>
    </tr>
    <tr>
      <td>We received a <font color="blue">letter dated as</font> of March 31, 2006, in which <font color="blue">the Durus </font>fund     stated  its intention, and confirmed its ability, to <font color="blue">provide financing</font>     <font color="blue">necessary</font> to fund our <font color="blue">operations</font> at least through January 1, 2007</td>
    </tr>
    <tr>
      <td>However,     this letter does not represent a <font color="blue">legally binding commitment</font> of <font color="blue">the Durus </font>    fund to provide the Company with any financing, and the <font color="blue">letter further</font>     provides that there are <font color="blue">no <font color="blue">third party</font> beneficiaries</font> to the letter</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">additional</font>  capital  that we are able to raise through <font color="blue">additional</font>     issuances of our <font color="blue"><font color="blue">equity securities</font> may</font> result in substantial dilution to our     then existing <font color="blue">stockholders</font>, and any <font color="blue">debt financing</font> we may be able to obtain     could result in the imposition of <font color="blue">significant</font> financial and operational     <font color="blue">restrictions</font> on us</td>
    </tr>
    <tr>
      <td>Should the financing we require to sustain our working     capital needs be unavailable or <font color="blue"><font color="blue">prohibitive</font>ly</font> expensive when we require it,     our business, operating results, <font color="blue">financial condition</font> and prospects could be     <font color="blue">materially</font> and <font color="blue">adversely</font> effected</td>
    </tr>
    <tr>
      <td>Customers, suppliers and other <font color="blue"><font color="blue">third parties</font> may</font> not do business with us,     <font color="blue">may terminate</font> business <font color="blue">relationships</font> with us or may not extend business     <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>Due to our capital <font color="blue">constraints</font>, vendors and other <font color="blue"><font color="blue">third parties</font> may</font> decide     not to conduct business with us, or may conduct business <font color="blue"><font color="blue">with us on</font>ly on</font> a     <font color="blue">cash basis</font> and on other terms that are less favorable than those <font color="blue">customarily</font>     <font color="blue">extended by them</font></td>
    </tr>
    <tr>
      <td>In that event, our <font color="blue">costs may increase</font></td>
    </tr>
    <tr>
      <td>In addition, our     capital <font color="blue">constraints</font> may make it <font color="blue">difficult</font> for us to market the <font color="blue">PHD System     </font>and related services to current and prospective customers</td>
    </tr>
    <tr>
      <td>If we are unable     to maintain <font color="blue">relationships</font> with existing clinics and/or develop <font color="blue">relationships</font>     <font color="blue">with new clinics</font>, our <font color="blue">future revenues <font color="blue">will likely</font> decrease</font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       We <font color="blue">currently rely on</font> a <font color="blue">few key customers</font> for a <font color="blue">significant</font> portion of our     sales</td>
    </tr>
    <tr>
      <td>We  currently  derive, and expect to continue to derive, a substantial     percentage of our <font color="blue">net sales from fewer than ten customers</font></td>
    </tr>
    <tr>
      <td>A loss of one or     more  of those <font color="blue">customers could</font> cause a <font color="blue">significant</font> decrease in our net     revenue</td>
    </tr>
    <tr>
      <td>Our <font color="blue">largest customers</font>, DaVita, the Dialysis Centers of Lincoln and     <font color="blue">Northwest Kidney Center </font>accounted for 16prca, 11prca and 8prca, respectively, of our     revenues (by dollar volume) for <font color="blue">fiscal year</font> 2005</td>
    </tr>
    <tr>
      <td>For <font color="blue">fiscal year</font> 2004, our     <font color="blue">largest customers</font>, Northwest Kidney Center, the Dialysis Centers of Lincoln     and Berkshire Medical Center accounted for 24prca, 10prca and 9prca, respectively, of     its <font color="blue">total revenue</font></td>
    </tr>
    <tr>
      <td>The amount of revenue we <font color="blue">derive from</font> a <font color="blue">specific customer</font>     is likely to <font color="blue">vary from period</font> to period, and a <font color="blue">major customer</font> in one period     may not produce <font color="blue">significant</font> <font color="blue">additional</font> revenue in a <font color="blue">subsequent period</font></td>
    </tr>
    <tr>
      <td>We     anticipate that our operating results <font color="blue">will continue</font> to <font color="blue">depend on sales</font> to a     small  number  of  key  customers in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Loss of a     <font color="blue">significant</font> amount of business from any of our large <font color="blue">customers could</font> have a     material adverse effect on our results of <font color="blue">operations</font> and <font color="blue">financial condition</font>     if such business were not substantially replaced by <font color="blue">additional</font> business from     existing or <font color="blue">new customers</font></td>
    </tr>
    <tr>
      <td>Additionally, our results of <font color="blue">operations</font> and     <font color="blue">financial condition</font> could be <font color="blue">materially</font> <font color="blue">adversely</font> affected if any of our     large customers experience financial <font color="blue">difficult</font>ies that cause them to delay,     or fail to make, payments for goods sold or leased to them</td>
    </tr>
    <tr>
      <td>If  our  current  <font color="blue">manufacturing</font>  <font color="blue">agreement</font> with Delphi Medical Systems     Corporation (“Delphi”) is terminated and we are required to <font color="blue">establish new</font>     <font color="blue">manufacturing</font> or parts sourcing <font color="blue">relationships</font>, we may experience increased     costs, disruptions in the <font color="blue">manufacture</font> and shipment of <font color="blue">PHD Systems </font>and a loss     of revenue</td>
    </tr>
    <tr>
      <td><font color="blue">The PHD System </font>is <font color="blue">manufacture</font>d by Delphi</td>
    </tr>
    <tr>
      <td>On October 8, 2005, Delphi and its     parent <font color="blue">corporation</font> filed a voluntary petition for business <font color="blue">reorganization</font>     under Chapter 11 of the <font color="blue">US Bankruptcy Code</font></td>
    </tr>
    <tr>
      <td>The ultimate effect of the     <font color="blue">bankruptcy on</font> our <font color="blue">relationship with</font> Delphi is unclear</td>
    </tr>
    <tr>
      <td>We have a Uniform     Commercial Code <font color="blue">financing statement on file with</font> the <font color="blue">Colorado Secretary </font>of     State  <font color="blue">with respect</font> to certain component <font color="blue">inventory <font color="blue">located at</font></font> Delphi’s     <font color="blue">warehouses</font></td>
    </tr>
    <tr>
      <td>In addition, as of <font color="blue">December </font>31, 2005, we had a <font color="blue">cash deposit</font> in     the amount of dlra1cmam432cmam000 with Delphi <font color="blue">as security</font> for certain of our purchase     <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>We  have  recorded  a reserve to reflect the <font color="blue">uncertainty</font>     <font color="blue">associated with</font> the bankruptcy filing; however, we are pursuing the full     value of the deposit</td>
    </tr>
    <tr>
      <td>We have had <font color="blue">ongoing <font color="blue">discussions with</font></font> Delphi regarding     our  <font color="blue">accounts payable balance</font>, our deposit and <font color="blue">certain parts inventory</font>     <font color="blue">located at</font> Delphi’s <font color="blue">warehouses</font></td>
    </tr>
    <tr>
      <td>In the first quarter of 2006, we received     <font color="blue">correspondence</font> from Delphi <font color="blue">advising us</font> of their decision to <font color="blue">stop further</font>     shipments of <font color="blue">PHD Systems </font>and parts until these items have been resolved</td>
    </tr>
    <tr>
      <td>We     plan to continue our <font color="blue">discussions with</font> Delphi and believe that we have a     sufficient inventory of parts and machines on hand to <font color="blue">enable us</font> to continue     <font color="blue">operations</font>  pending  resolution  of this matter</td>
    </tr>
    <tr>
      <td>If Delphi rejects our     <font color="blue">manufacturing</font> <font color="blue">agreement</font> in <font color="blue">connection with</font> its <font color="blue">bankruptcy proceeding</font> or we     are unable to <font color="blue">settle open issues with</font> Delphi on a <font color="blue">timely basis</font>, we would be     forced  to  establish  new  <font color="blue">manufacturing</font> and/or direct parts sourcing     <font color="blue">relationships</font> which could expose us to a number of risks and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>These   risks   and   <font color="blue">uncertainties</font>  could  include  whether  the  new     <font color="blue">manufacture</font>r(s) and parts <font color="blue">suppliers will</font> agree to do business <font color="blue">with us on</font>     satisfactory  terms  as well as whether such <font color="blue">manufacture</font>s(s) and parts     <font color="blue">suppliers will</font> perform to our <font color="blue">expectations</font> and produce <font color="blue">the PHD System </font>and     supply parts in a timely, cost-efficient manner on a <font color="blue">consistent basis</font> and in     <font color="blue">accordance with</font> all regulatory <font color="blue">requirement</font>s including QSRs</td>
    </tr>
    <tr>
      <td>Any of these     risks  could  make  it  <font color="blue">difficult</font>  for us to produce <font color="blue">the PHD System </font>on     satisfactory <font color="blue">commercial terms</font>, if at all</td>
    </tr>
    <tr>
      <td>We have a history of operating losses and a <font color="blue">significant</font> <font color="blue">accumulated deficit</font>,     and we may not achieve or maintain <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">been profitable since</font> our inception in January 1991</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31,  2005,  we  had  an  <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font>     dlra190dtta8 million</td>
    </tr>
    <tr>
      <td>We expect to continue to incur <font color="blue">additional</font> losses for the     foreseeable  future as a result of a <font color="blue">high level</font> of operating expenses,     <font color="blue">significant</font> up-front <font color="blue">expenditure</font>s, production and <font color="blue">marketing activities</font> and     very limited <font color="blue">revenue from</font> our core business</td>
    </tr>
    <tr>
      <td>We may never realize       24     ______________________________________________________________________       <font color="blue">significant</font> revenues from our core business or be profitable</td>
    </tr>
    <tr>
      <td>Factors that     <font color="blue">will influence</font> the timing and amount of our <font color="blue">profitability</font> include:       ·        the success of the product <font color="blue">development</font> <font color="blue">efforts under</font> the DEKA     Agreement;       ·       our ability to obtain <font color="blue">sufficient financing</font> to operate our business;       ·       <font color="blue">market <font color="blue">acceptance</font></font> of the PHD System;       ·       our success in <font color="blue">commercializing</font> the PHD System;       ·       our ability to <font color="blue"><font color="blue">effective</font>ly</font> and efficiently <font color="blue">manufacture</font>, market and     distribute the PHD System; and       ·       our ability to sell or lease <font color="blue">the PHD System </font>and related services at     a price that covers our per unit costs, which result may be <font color="blue">difficult</font> to     achieve,  in  part  because  of  the  <font color="blue">significant</font>  <font color="blue">restrictions</font> on the     <font color="blue">reimbursement</font> of <font color="blue">dialysis treatment</font> by <font color="blue">the Medicare </font>program, as discussed     below, and the high cost of <font color="blue">manufacturing</font> the PHD System</td>
    </tr>
    <tr>
      <td>We face <font color="blue">significant</font> <font color="blue">challenges</font> in shifting from the <font color="blue">development</font> stage to the     <font color="blue"><font color="blue">commercialization</font> stage</font> for the PHD System</td>
    </tr>
    <tr>
      <td>Our <font color="blue">prospects must</font> be considered     in light of the risks, expenses and <font color="blue">difficult</font>ies <font color="blue">frequently</font> encountered in     such a transition, and there can be no assurance that we will have any     <font color="blue">significant</font> revenues or that we will ever achieve profitable <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our cost to produce <font color="blue">the PHD System </font>and deliver related services and supplies     currently exceeds the <font color="blue">market price</font> of <font color="blue">the PHD System </font>and related services     and supplies</td>
    </tr>
    <tr>
      <td>The  pricing  of  the  PHD System and related services and supplies is     constrained by <font color="blue">limitations</font> on <font color="blue"><font color="blue">government</font>al</font> and <font color="blue">third party</font> <font color="blue">reimbursement</font>     programs</td>
    </tr>
    <tr>
      <td>Although we are working to reduce the cost of servicing the     machine and we are attempting to reduce <font color="blue">manufacturing</font> costs by identifying     <font color="blue"><font color="blue">alternative</font> materials</font> and suppliers, there can be no assurance that these     <font color="blue"><font color="blue">efforts will</font> <font color="blue">enable us</font></font> to achieve profitable <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, the cost of services and supplies for <font color="blue">the PHD System </font>currently     exceeds the <font color="blue">market price</font> as a result of the need to have a <font color="blue">local presence</font> of     <font color="blue">field service</font> and <font color="blue">clinical service personnel</font> in <font color="blue">each geographical area</font> that     <font color="blue">PHD Systems </font>are sold</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">the PHD System </font>is comprised of new,     complex, highly automated <font color="blue">technologies</font>, which operate in a <font color="blue">rigorous process</font></td>
    </tr>
    <tr>
      <td>While we continue to realize <font color="blue">improvements</font> in the PHD System’s <font color="blue">re<font color="blue">liability</font></font> as     a result of the <font color="blue">acquisition</font> and <font color="blue">development</font> of new parts and subsystems,     there can be no assurance that we will be successful in <font color="blue">reaching industry</font>     norms for <font color="blue">re<font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to improve the <font color="blue">re<font color="blue">liability</font></font> of the     PHD System, our operating <font color="blue">costs will</font> be <font color="blue">adversely</font> impacted and we may never     achieve <font color="blue">profitability</font> as a result</td>
    </tr>
    <tr>
      <td><font color="blue">If a PHD System </font>is unavailable for <font color="blue">treatments</font> for more than a few days, the     <font color="blue">patient assigned</font> to the machine must go back to his <font color="blue">dialysis clinic</font> for     in-center treatment until his PHD System is repaired</td>
    </tr>
    <tr>
      <td>Although we have     experienced infrequent incidents of <font color="blue">patients on</font> <font color="blue">the PHD System </font>needing to go     back in center for <font color="blue">treatments</font> to date, we <font color="blue">cannot assure</font> you, <font color="blue">based on</font> our     limited experience that <font color="blue">such incidents will</font> not occur more <font color="blue">frequently</font> in the     future</td>
    </tr>
    <tr>
      <td>Our business will fail if we <font color="blue">cannot successfully commercialize</font> the PHD     System; because we have <font color="blue">only recently begun</font> this <font color="blue"><font color="blue">commercialization</font> process</font>,     our <font color="blue">success cannot</font> be predicted and is uncertain</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent</font>     on many <font color="blue">variables entirely outside</font> of our control</td>
    </tr>
    <tr>
      <td>Acceptance of <font color="blue">the PHD System </font>in the <font color="blue">marketplace by both potential users</font> and     purchasers (two separate groups with at times <font color="blue">conflicting</font> interests) is     uncertain,  and  failure  to achieve sufficient <font color="blue">market <font color="blue">acceptance</font></font> will     <font color="blue">significant</font>ly limit our ability to <font color="blue">generate revenue</font> and <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>The success of <font color="blue">the PHD System </font>is <font color="blue">dependent</font> on many variables, including its     safety, price, <font color="blue">re<font color="blue">liability</font></font>, <font color="blue">effective</font>ness and       25     ______________________________________________________________________       cost-<font color="blue">effective</font>ness as an <font color="blue"><font color="blue">alternative</font> dialysis modality</font></td>
    </tr>
    <tr>
      <td>The failure to     <font color="blue">conclusively <font color="blue">demonstrate</font> each</font> of these factors could <font color="blue">significant</font>ly hinder     <font color="blue">market <font color="blue">acceptance</font></font> of our PHD System, and the failure of our PHD System to     achieve sustained commercial viability or <font color="blue">market <font color="blue">acceptance</font></font> would have a     material  adverse  effect  on  us and your <font color="blue">investment</font> in us</td>
    </tr>
    <tr>
      <td>Moreover,     successful <font color="blue">commercialization</font> will depend upon, among other things, market     <font color="blue">acceptance</font>  of  the  efficacy of <font color="blue">daily <font color="blue">hemodialysis</font></font></td>
    </tr>
    <tr>
      <td>This will require     substantial <font color="blue">marketing efforts</font> and the <font color="blue">expenditure</font> of <font color="blue">significant</font> funds by us     to inform nephrologists, <font color="blue">dialysis clinic</font>s, other <font color="blue">healthcare providers</font> and     dialysis  patients of the benefits of <font color="blue">daily <font color="blue">hemodialysis</font></font>, and thus the     benefits of the PHD System</td>
    </tr>
    <tr>
      <td>In marketing the PHD System, we may encounter <font color="blue">significant</font> clinical and     <font color="blue">market resistance</font> to:       ·       using the PHD System;       ·       home <font color="blue">hemodialysis</font>, which is <font color="blue">currently employed by only</font> a small     percentage of patients suffering from end-stage renal disease; and       ·       <font color="blue">daily <font color="blue">hemodialysis</font></font>, which to our knowledge has never been a widely     <font color="blue">implemented dialysis <font color="blue">alternative</font></font></td>
    </tr>
    <tr>
      <td>There can be no assurance that our <font color="blue">efforts will</font> be successful or that the     PHD System will ever achieve <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">PHD System     </font>is a personal system, designed for use by a <font color="blue">single patient</font>, and requires     <font color="blue">several hours</font> after a <font color="blue">dialysis treatment</font> to prepare itself for the next     <font color="blue">treatment session</font></td>
    </tr>
    <tr>
      <td>As such, it is very unlikely to be used in the prevailing     method  of  outpatient <font color="blue">hemodialysis</font>, which <font color="blue">generally</font> involves treating     <font color="blue">patients three times per week</font> for <font color="blue">treatment session</font>s lasting between three     and  four  hours</td>
    </tr>
    <tr>
      <td>In this <font color="blue">prevailing method</font> of <font color="blue">hemodialysis</font>, patients     receiving <font color="blue">treatment on</font> a given day are treated in shifts, with <font color="blue">patients on</font>     succeeding shifts <font color="blue">using dialysis machines employed during prior</font> shifts</td>
    </tr>
    <tr>
      <td>A number of other <font color="blue">factors will affect</font> the <font color="blue">future success</font> and sales of our     product</td>
    </tr>
    <tr>
      <td>These factors include:       ·       the amount of <font color="blue">government</font> and private <font color="blue">reimbursement</font> for dialysis     treatment;       ·       whether the <font color="blue">system will</font> be safe or <font color="blue">effective</font> or whether it will be     cost-<font color="blue">effective</font> relative to other <font color="blue">dialysis treatment</font> <font color="blue"><font color="blue">alternative</font>s</font>;       ·       whether <font color="blue">daily <font color="blue">hemodialysis</font></font> will be shown to be more <font color="blue">clinically</font>     <font color="blue">effective</font> than <font color="blue">alternative</font> dialysis modalities;       ·       <font color="blue">whether patients will</font> be reluctant to <font color="blue">administer</font> and monitor the PHD     System with limited or <font color="blue">no supervision</font>; and       ·       <font color="blue">whether there</font> are unexpected side effects, complications or other     safety issues <font color="blue">associated with</font> <font color="blue">daily <font color="blue">hemodialysis</font></font> (or the PHD System) that     may <font color="blue">adversely</font> affect the market for our products and services</td>
    </tr>
    <tr>
      <td>We are entirely <font color="blue">dependent</font> on the PHD System, our <font color="blue">sole product</font></td>
    </tr>
    <tr>
      <td>Since our inception, we have <font color="blue">devoted substantially</font> all of our efforts to the     <font color="blue">development</font> of the PHD System</td>
    </tr>
    <tr>
      <td>We expect to be entirely <font color="blue">dependent</font> for the     <font color="blue">foreseeable future</font> on sales of, and services relating to, <font color="blue">the PHD System </font>for     revenues</td>
    </tr>
    <tr>
      <td>Our <font color="blue">dependence on</font> a <font color="blue">single product</font> creates <font color="blue">significant</font> risk for     our company and <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       Our strategy to develop a <font color="blue">new generation</font> of our <font color="blue">product under</font> the DEKA     Agreement involves a number of risks and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our strategy for <font color="blue">development</font> of a <font color="blue">new generation</font> of our <font color="blue">product depends upon</font>     the success of the DEKA Agreement</td>
    </tr>
    <tr>
      <td>The <font color="blue">ultimate success</font> of the <font color="blue">development</font>     <font color="blue">efforts under</font> the <font color="blue">DEKA Agreement </font>is subject to a number of cost, timing and     other risks and <font color="blue">uncertainties</font>, many of which are outside of our control</td>
    </tr>
    <tr>
      <td>We     cannot be certain that the <font color="blue">DEKA Agreement </font>will be successful or that any     <font color="blue">product will ultimately</font> be developed under this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainty  </font>and  amount of third-party <font color="blue">reimbursement</font> could affect our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">most private insurance policies cover</font> a substantial portion of the     cost of <font color="blue">dialysis treatment</font> in the <font color="blue">United States</font>, <font color="blue">most patients</font> receiving     <font color="blue">dialysis treatment</font> in the <font color="blue"><font color="blue">United States</font> </font>are <font color="blue">insured by</font> <font color="blue">Medicare or Medicaid</font></td>
    </tr>
    <tr>
      <td><font color="blue">Medicare and Medicaid </font>provide <font color="blue">reimbursement</font> for <font color="blue">dialysis treatment</font> at set     composite rates, which have not increased <font color="blue">significant</font>ly since 1983</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can be no assurance that the current <font color="blue">limitations</font> or <font color="blue">requirement</font>s on Medicare     and Medicaid <font color="blue">reimbursement</font> for <font color="blue">dialysis will</font> not have a <font color="blue">materially</font> adverse     effect  on  the  market for the PHD System, that <font color="blue">health administration</font>     <font color="blue">authorities outside</font> of the <font color="blue"><font color="blue">United States</font> </font>will provide <font color="blue">reimbursement</font> at     acceptable levels or at all or that current or future <font color="blue">reimbursement</font> rates     will be sufficient to <font color="blue">enable us</font> to maintain <font color="blue">prices at levels sufficient</font> to     <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>and <font color="blue">technological</font> advances could cause us to lose current and     future business <font color="blue">opportunities</font> and <font color="blue">materially</font> harm our results of <font color="blue">operations</font>     and ability to grow</td>
    </tr>
    <tr>
      <td>The  dialysis  industry is <font color="blue">characterized by competition</font> for financing,     executive talent, intellectual property, and, ultimately, product sales</td>
    </tr>
    <tr>
      <td>Our     primary  <font color="blue"><font color="blue">competitor</font>s</font> in supplying dialysis equipment, disposables, and     services are Fresenius Medical Care AG, Baxter International, Inc, and     <font color="blue">Gambro AB These </font><font color="blue"><font color="blue">competitor</font>s</font> have more financial, scientific, and technical     resources  than  do  we,  as  well  as more experience <font color="blue">with respect</font> to     <font color="blue">manufacturing</font>, product <font color="blue">development</font>, and marketing in the <font color="blue">dialysis market</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">also compete with</font> NxStage Medical, Inc</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">competitor</font>s</font> succeed in     developing products that are more <font color="blue">effective</font> and/or less costly than the PHD     System for performing more frequent home <font color="blue">hemodialysis</font>, both our sales and     our prospects for achieving <font color="blue">profitability</font> may be <font color="blue">adversely</font> impacted</td>
    </tr>
    <tr>
      <td>We also     expect that the number of our <font color="blue"><font color="blue">competitor</font>s</font> will increase, and there can be no     assurance  that  we  will  be able to <font color="blue">compete successfully against</font> any     <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>Our  ability to <font color="blue">successfully market</font> our products and <font color="blue">services could</font> be     <font color="blue">adversely</font>  impacted  by  <font color="blue">pharmacological</font> and <font color="blue">technological</font> advances in     preventing the progression of ESRD in patients (such as those with diabetes     and <font color="blue">hypertension</font>), <font color="blue">technological</font> <font color="blue">development</font>s by others, <font color="blue">development</font> of new     <font color="blue">medications</font> designed to reduce the incidence of kidney transplant rejection     and progress in using kidneys harvested from genetically-engineered animals     as a source of <font color="blue">transplants</font></td>
    </tr>
    <tr>
      <td>Furthermore, although home hemo<font color="blue">dialysis treatment</font> options are available,     adoption has been limited</td>
    </tr>
    <tr>
      <td>The <font color="blue">most widely adopted</font> form of <font color="blue">dialysis therapy</font>     used in a setting other than a <font color="blue">dialysis clinic</font> is <font color="blue">peritoneal dialysis</font></td>
    </tr>
    <tr>
      <td>Because the adoption of home <font color="blue">hemodialysis</font> has been limited to date, the     number of patients who desire to, and are capable of, <font color="blue">administer</font>ing their     own hemo<font color="blue">dialysis treatment</font> is unknown and there is limited <font color="blue">data upon which</font>     to  make  estimates</td>
    </tr>
    <tr>
      <td>Our long-term growth will depend on the number of     patients who adopt home-based <font color="blue">hemodialysis</font> and how quickly they adopt it</td>
    </tr>
    <tr>
      <td>We     cannot be certain that this <font color="blue">market will</font> develop, how quickly it will develop     or how large it will be</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future sales could</font> be <font color="blue">adversely</font> affected due to our limited marketing     experience</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently market</font> our products and <font color="blue">services primarily through</font> our own     <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able to staff an     <font color="blue">adequate marketing staff</font> or <font color="blue">sales force</font> or that the cost of such       27     ______________________________________________________________________       will not be <font color="blue">prohibitive</font>, or that our <font color="blue">direct sales</font> and <font color="blue">marketing efforts</font> will     be  successful</td>
    </tr>
    <tr>
      <td>The choice of <font color="blue">dialysis therapy</font> involves the successful     marketing  to  <font color="blue">dialysis clinic</font> operators and nurses, nephrologists and     patients, each of which may have <font color="blue">different factors</font> that they consider in     making their decision</td>
    </tr>
    <tr>
      <td>In<font color="blue">effective</font> marketing to any one of these decision     makers  may <font color="blue">adversely</font> affect <font color="blue">acceptance</font> of the PHD System</td>
    </tr>
    <tr>
      <td>We may have     <font color="blue">difficult</font>y in gaining <font color="blue">acceptance</font> of <font color="blue">the PHD System </font>for a number of factors     including:       ·       the <font color="blue">failure by us</font> to <font color="blue">demonstrate</font> to patients, operators of dialysis     clinics, nephrologists, dialysis nurses and others that our product is     equivalent or superior to <font color="blue">existing therapy options</font>, or that the cost or risk     associated  with  use  of  our  product  is not <font color="blue">greater than available</font>     <font color="blue"><font color="blue">alternative</font>s</font>;       ·       competition from products sold by companies with longer operating     histories and <font color="blue">greater financial resources</font>, more <font color="blue">recognizable</font> brand names and     better established <font color="blue">distribution</font> networks and <font color="blue">relationships</font> with dialysis     clinics;       ·       the ownership and operation of some <font color="blue">dialysis providers by companies</font>     that also <font color="blue">manufacture</font> and <font color="blue">sell competitive <font color="blue">dialysis products</font></font>;       ·       the <font color="blue">introduction</font> of <font color="blue">competing products</font> or <font color="blue">treatments</font> that may be     more <font color="blue">effective</font>, safer, easier to use or <font color="blue">less expensive than ours</font>;       ·        the  number  of  <font color="blue">patients willing</font> and able to perform therapy     in<font color="blue">dependent</font>ly, outside of a traditional <font color="blue">dialysis clinic</font>, may be <font color="blue">smaller than</font>     we estimate; and       ·        the <font color="blue">continued availability</font> of satisfactory <font color="blue">reimbursement</font> from     <font color="blue">healthcare payers</font>, including Medicare</td>
    </tr>
    <tr>
      <td>We are subject to extensive <font color="blue">government</font> regulation, which can be costly, time     consuming and subject us to <font color="blue">unanticipated <font color="blue">interruption</font>s</font> or delays in our     commercial <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The  PHD  System, our <font color="blue">sole product</font>, is subject to stringent <font color="blue">government</font>     regulation in the <font color="blue"><font color="blue">United States</font> </font>and other countries</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>,     <font color="blue">the PHD System </font>is <font color="blue">regulated as</font> a medical device by the FDA In March 2002,     we announced receipt of <font color="blue">clearance from</font> the FDA to market <font color="blue">the PHD System </font>in     the  <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The FDA clearance had no <font color="blue">restrictions</font> and included     <font color="blue">authorization</font> to use the product in the home; however, FDA <font color="blue">clearance under</font>     510(k) is subject to <font color="blue">continual review</font> and <font color="blue">later discovery</font> of <font color="blue">previously</font>     unknown  problems  may  result in <font color="blue">restrictions</font> on product marketing or     withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>In the European Economic Area, <font color="blue">the PHD System </font>is <font color="blue">regulated as</font> a medical     device under the <font color="blue">Medical Device Directive</font></td>
    </tr>
    <tr>
      <td>In October 2002, we announced     receipt of <font color="blue">EC Certification for CE Mark </font><font color="blue">approval pursuant</font> to the Medical     Device Directive</td>
    </tr>
    <tr>
      <td>The <font color="blue">certification approved</font> <font color="blue">the PHD System </font>for home use</td>
    </tr>
    <tr>
      <td>Such approval was required prior to the <font color="blue">commercialization</font> of the <font color="blue">PHD System     </font>in the European Economic Area</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">government</font> <font color="blue">regulations</font> may be established or imposed in the     United  States or the European Economic Area, or the <font color="blue">interpretation</font> or     <font color="blue">enforcement</font> of <font color="blue">such <font color="blue">regulations</font> may</font> change, which could <font color="blue">materially</font> impact     the  <font color="blue">regulatory clearances</font> we have received for <font color="blue">the PHD System </font>and its     continued <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In addition, various statutes and <font color="blue"><font color="blue">regulations</font> also govern</font> the testing,     labeling,  storage,  record  keeping,  <font color="blue">distribution</font>,  sale, marketing,     <font color="blue">advertising</font>  and  promotion of our products, which present <font color="blue">significant</font>     compliance  burdens for our company</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable     <font color="blue">requirement</font>s can result in fines, recalls or seizures of products, total or     partial suspension of production, withdrawal of existing product approvals     or clearances, refusal to approve or clear new <font color="blue"><font color="blue">application</font>s</font> or notices and     criminal <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of <font color="blue">the PHD System </font><font color="blue">must also comply</font> or <font color="blue">ensure <font color="blue">compliance with</font></font>     current QSR <font color="blue"><font color="blue">regulations</font> promulgated by</font> the FDA We may be required to expend     time, resources and effort in product       28     ______________________________________________________________________       <font color="blue">manufacturing</font> and <font color="blue">quality control</font> to <font color="blue">ensure compliance even though</font> our PHD     System is <font color="blue">manufacture</font>d currently by an in<font color="blue">dependent</font> contractor</td>
    </tr>
    <tr>
      <td>If violations     of  the  applicable  <font color="blue">regulations</font>  are  noted during FDA <font color="blue">inspections</font> of     <font color="blue">manufacturing</font> facilities, it may have a material adverse effect on the     <font color="blue">continued marketing</font> of our products</td>
    </tr>
    <tr>
      <td>You <font color="blue">should also</font> be aware that proper <font color="blue">regulatory approvals</font> have not been     completed in any <font color="blue">jurisdictions</font> other than the <font color="blue"><font color="blue">United States</font> </font>and the European     Economic Area</td>
    </tr>
    <tr>
      <td>There can be no assurance or guarantee that any of these     <font color="blue">approvals will</font> be obtained in a <font color="blue">timely manner</font> or at all</td>
    </tr>
    <tr>
      <td>We rely on in<font color="blue">dependent</font> contract <font color="blue">manufacture</font>rs for the <font color="blue">manufacture</font> of our PHD     System</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">manufacture</font> the PHD System, and our <font color="blue">dependence on</font>     in<font color="blue">dependent</font>  <font color="blue">contractors</font>,  may delay or impair our ability to generate     revenues, or <font color="blue">adversely</font> affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>To  be  successful,  our PHD System must be <font color="blue">manufacture</font>d in commercial     quantities and at acceptable cost</td>
    </tr>
    <tr>
      <td><font color="blue">Production </font>of this product, <font color="blue">especially</font> in     commercial quantities, will create technical as well as financial <font color="blue">challenges</font>     for us</td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter unexpected delays</font> or costs in the scale-up of     <font color="blue">manufacturing</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">manufacturing</font> or <font color="blue">quality control</font> problems     may  arise  (and among other <font color="blue">things increase</font> our costs) as we increase     production of <font color="blue">the PHD System </font>or as <font color="blue">additional</font> <font color="blue">manufacturing</font> <font color="blue">capacity</font> is     required in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently rely on</font> single contract <font color="blue">manufacture</font>rs to <font color="blue">manufacture</font> each of     the <font color="blue">major <font color="blue">components</font></font> of the PHD System</td>
    </tr>
    <tr>
      <td>Such <font color="blue">contractors</font> are not employed or     <font color="blue">otherwise controlled by us</font> and are <font color="blue"><font color="blue">generally</font> free</font> to conduct their business     at their own <font color="blue">discretion</font></td>
    </tr>
    <tr>
      <td>Although certain of our contract <font color="blue">manufacture</font>rs have     <font color="blue">entered into contracts with us</font> to <font color="blue">manufacture</font> <font color="blue">components</font> of the PHD System,     <font color="blue">such contracts</font> can be <font color="blue">terminated at</font> any time <font color="blue">under certain circumstances by</font>     us or by the <font color="blue">contractors</font>, and can be <font color="blue">breached at</font> any time</td>
    </tr>
    <tr>
      <td>Further, work     stoppages and the slowing of <font color="blue">production at</font> a single in<font color="blue">dependent</font> contractor     would have a material adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There are also other <font color="blue">risks inherent</font> in using a <font color="blue">single source</font> of supply</td>
    </tr>
    <tr>
      <td>We     have not made <font color="blue">alternative</font> <font color="blue">arrangements</font> for the <font color="blue">manufacture</font> of the major     <font color="blue">components</font> of <font color="blue">the PHD System </font>and we may not be able to implement acceptable     <font color="blue">alternative</font> <font color="blue">arrangements</font> on a <font color="blue">timely basis</font>, or at all</td>
    </tr>
    <tr>
      <td>It is likely that a     <font color="blue">significant</font>  <font color="blue">interruption</font> in <font color="blue">supply would</font> result if we utilize or were     required to utilize a different <font color="blue">manufacturing</font> contractor for any of the     <font color="blue">major <font color="blue">components</font></font> of PHD Systems</td>
    </tr>
    <tr>
      <td>The loss of the services of any of our     contract <font color="blue">manufacture</font>rs would have a <font color="blue">materially</font> adverse effect on our results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>See “<font color="blue">Risk Factors</font>—If our current <font color="blue">manufacturing</font> <font color="blue">agreement</font>     with Delphi is terminated and we are required to <font color="blue">establish new</font> <font color="blue">manufacturing</font>     <font color="blue">relationships</font>,  we  may experience increased costs, disruptions in the     <font color="blue">manufacture</font> and shipment of <font color="blue">the PHD System </font>and a loss of revenue</td>
    </tr>
    <tr>
      <td>”  In     addition, we or our <font color="blue">manufacture</font>rs may not be able to obtain, on a timely     basis, <font color="blue">components</font> or other supplies <font color="blue">necessary</font> to <font color="blue">manufacture</font> or use the PHD     System</td>
    </tr>
    <tr>
      <td>We may not be able to protect our <font color="blue">intellectual property rights</font> and, as a     result, we <font color="blue">could lose competitive advantages</font> that could <font color="blue">adversely</font> affect our     operating results</td>
    </tr>
    <tr>
      <td>Our  success  depends,  in part, on our ability and the ability of our     <font color="blue">licensors</font> to obtain, assert and defend patent rights, protect <font color="blue">trade secrets</font>     and  operate  without  infringing the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>We     currently own or have rights in <font color="blue">relevant fields</font> to 47 US patents and 26     <font color="blue">foreign patents</font></td>
    </tr>
    <tr>
      <td>There can be no assurance, however, that:       ·       we will be able to obtain <font color="blue">additional</font> licenses to patents of others     or that we will be able to develop <font color="blue">additional</font> patentable technology of our     own;       ·       any <font color="blue">patents issued</font> to us will provide us with competitive advantages     or that the patents or <font color="blue">proprietary</font> rights of <font color="blue">others will</font> not have an adverse     effect on our ability to do business;       29     ______________________________________________________________________       ·       <font color="blue">others will</font> not in<font color="blue">dependent</font>ly develop similar products;       ·        others  will  not  design  around or <font color="blue">infringe <font color="blue">such patents</font></font> or     <font color="blue">proprietary</font> rights owned by or licensed to us; and       ·       any patent obtained or <font color="blue">licensed by us will</font> be held to be valid and     enforceable if <font color="blue">challenged by</font> another party</td>
    </tr>
    <tr>
      <td>We are aware that <font color="blue">numerous patents</font> have <font color="blue">been issued</font> relating to methods of     dialysis</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  endeavor  to  protect  our <font color="blue">patent rights from</font>     <font color="blue">infringement</font>, it is possible that by virtue of the <font color="blue">numerous patents</font> that     have been, or <font color="blue">potentially will</font> be, issued relating to <font color="blue">hemodialysis</font> methods,     we may not be aware, or <font color="blue">become aware</font>, of <font color="blue">patents issued</font> to our <font color="blue"><font color="blue">competitor</font>s</font>     or  others  that <font color="blue">conflict with</font> our own or those of our <font color="blue">licensors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">conflicts could</font> result in a rejection of important patent <font color="blue"><font color="blue">application</font>s</font> or     the <font color="blue">invalidation</font> of important patents, which could have a material adverse     effect on our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>In the event of such conflicts, or in     the event we believe that <font color="blue">competitive products infringe patents</font> to which we     hold rights, we may pursue patent <font color="blue">infringement</font> <font color="blue">litigation</font> or <font color="blue">interference</font>     <font color="blue"><font color="blue">proceedings</font> against</font>, or may be required to <font color="blue">defend against such <font color="blue">litigation</font></font> or     <font color="blue">proceedings</font> involving, holders of <font color="blue">such <font color="blue">conflicting</font> patents</font> or competing     products</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font> or <font color="blue">proceedings</font> may have a material adverse effect     on  our <font color="blue">competitive position</font>, and we may not be successful in any such     <font color="blue">litigation</font> or proceeding</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>and other <font color="blue">proceedings</font> relating to     patent matters, whether initiated by us or a <font color="blue">third party</font>, can be expensive     and time consuming, regardless of whether the outcome is favorable to us,     and can result in the diversion of substantial financial, managerial and     other  resources</td>
    </tr>
    <tr>
      <td>An  <font color="blue">adverse outcome could</font> subject us to <font color="blue">significant</font>     <font color="blue">liabilities</font> to <font color="blue">third parties</font> or require us to cease any related <font color="blue">development</font>     or  <font color="blue">commercialization</font> activities</td>
    </tr>
    <tr>
      <td>In addition, if patents that contain     dominating or <font color="blue">conflicting</font> claims have been or are <font color="blue"><font color="blue">subsequently</font> issued</font> to     others and such claims are ultimately determined to be valid, we may be     required to obtain <font color="blue">licenses under patents</font> or other <font color="blue">proprietary</font> rights of     others</td>
    </tr>
    <tr>
      <td>The licenses required under any <font color="blue">such patents</font> or <font color="blue">proprietary</font> rights     may not be made <font color="blue">available on terms</font> acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>If we do not     obtain <font color="blue">such licenses</font>, we <font color="blue">could encounter delays</font> or could find that the     <font color="blue">development</font>, <font color="blue">manufacture</font> or sale of products requiring <font color="blue">such licenses</font> is     foreclosed which may <font color="blue">adversely</font> affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">proprietary</font> know-how and <font color="blue">confidential</font> information and employ     various  methods, such as entering into <font color="blue">confidential</font>ity and noncompete     <font color="blue">agreement</font>s with our <font color="blue">current employees</font> and with certain <font color="blue">third parties</font> to whom     we  have  divulged  <font color="blue">proprietary</font> information, to protect the processes,     concepts, ideas and documentation <font color="blue">associated with</font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">methods may</font> not afford <font color="blue">significant</font> protection to us, and we may not be able     to  protect  <font color="blue">adequately</font>  our <font color="blue">trade secrets</font> or our <font color="blue"><font color="blue">competitor</font>s</font> or other     <font color="blue">companies may</font> acquire information that we consider <font color="blue">proprietary</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims <font color="blue">may reduce demand</font> for <font color="blue">the PHD System </font>or result in     damages that exceed our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Our  business <font color="blue">exposes us</font> to potential product <font color="blue">liability</font> risks that are     inherent in the production, marketing and sale of <font color="blue">dialysis products</font></td>
    </tr>
    <tr>
      <td>We     currently maintain product <font color="blue">liability</font> insurance with a <font color="blue">coverage limit</font> of dlra10     million</td>
    </tr>
    <tr>
      <td>Our <font color="blue">insurance policy may</font> not <font color="blue">provide adequate protection against</font>     potential claims</td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">agreement</font>s with contract <font color="blue">manufacture</font>rs     require us to maintain product <font color="blue">liability</font> insurance, and the failure to     obtain such insurance could <font color="blue">materially</font> and <font color="blue">adversely</font> affect our ability to     produce our PHD System</td>
    </tr>
    <tr>
      <td>A successful claim <font color="blue">brought against us</font> in excess of     any <font color="blue">insurance coverage</font> obtained by us could have a material adverse effect     upon  our  business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In     addition, we have agreed to <font color="blue">indemnify certain</font> of our contract <font color="blue">manufacture</font>rs     against certain <font color="blue">liabilities</font> resulting from the use of our PHD System</td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________       Our <font color="blue"><font color="blue">recent cost reduction</font> <font color="blue">initiatives may</font></font> make it <font color="blue">difficult</font> for us to retain     and <font color="blue">hire <font color="blue">critical personnel</font></font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">dependent</font>  upon the services of our <font color="blue">senior executives</font> and key     <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>We do not maintain key-man life insurance on our     <font color="blue">senior executives</font></td>
    </tr>
    <tr>
      <td>In addition, we do not have employment <font color="blue">agreement</font>s, other     than certain severance, <font color="blue">confidential</font>ity and non-competition <font color="blue">agreement</font>s, with     any of our personnel</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">would likely</font> be <font color="blue">interrupted</font> if we lost     the services of our <font color="blue">senior executives</font> or key employees, which could have a     material adverse effect on <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Also, our continued <font color="blue">commercialization</font>     will  depend  upon,  among other things, the <font color="blue">successful recruiting</font> and     retention  of  highly  <font color="blue">skilled managerial</font> and <font color="blue">marketing personnel with</font>     experience in business <font color="blue">activities such as</font> those we contemplate</td>
    </tr>
    <tr>
      <td><font color="blue">Competition     </font>for the type of <font color="blue">highly skilled individuals sought by us</font> is intense, and we     may not be able to retain <font color="blue">existing employees</font> or find, attract and retain     other <font color="blue">skilled personnel on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>Our <font color="blue">recent cost reduction</font>     <font color="blue">initiatives may</font> make it <font color="blue">difficult</font> to retain <font color="blue">critical personnel</font> or replace     personnel who leave</td>
    </tr>
    <tr>
      <td>In addition, due to the declines in the price of our     <font color="blue">common stock</font>, the <font color="blue">exercise price</font> of <font color="blue">outstanding employee stock options</font>     <font color="blue">substantially exceeds</font> the <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These factors     may affect our ability to retain critical employees, which could seriously     harm our ability to <font color="blue">generate revenue</font>, manage day-to-day <font color="blue">operations</font>, and     deliver our products and services</td>
    </tr>
    <tr>
      <td>If we cannot develop adequate <font color="blue">distribution</font>, customer service and technical     <font color="blue">support networks</font>, we may not be able to market and distribute our <font color="blue">PHD System     </font><font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>Our strategy involves contracting with dialysis providers to have us supply     to  <font color="blue">dialysis patients</font> the PHD System, dialysate and other <font color="blue">consumables</font>,     patient training, customer service and maintenance and other technical     service</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able to organize these <font color="blue">networks on</font>     a  cost-<font color="blue">effective</font>  basis</td>
    </tr>
    <tr>
      <td>The failure to establish these <font color="blue">networks on</font> a     cost-<font color="blue">effective</font> basis would have a material adverse effect on our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not realize any of the anticipated <font color="blue">benefits from</font> our more focused     <font color="blue">resource allocation</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>6, 2005, we announced a plan to realign our <font color="blue">service network by</font>     <font color="blue">designating geographic</font> operating <font color="blue">districts which</font> have shown the highest     <font color="blue">adoption rates</font> of the PHD System</td>
    </tr>
    <tr>
      <td>The plan includes <font color="blue">several operational</font>     changes designed to <font color="blue">significant</font>ly reduce our <font color="blue">cash burn rate</font> and provide a     more focused <font color="blue">resource allocation</font></td>
    </tr>
    <tr>
      <td>We are focusing our sales and servicing     <font color="blue">efforts on</font> these <font color="blue">target markets</font></td>
    </tr>
    <tr>
      <td>While our decision to realign our operating     <font color="blue">model through</font> the <font color="blue">designation</font> of <font color="blue"><font color="blue">PHD Operating Districts</font> </font>may strengthen our     <font color="blue">relationships</font>  with  patients  and clinics in <font color="blue">designated areas</font>, it may     <font color="blue">adversely</font> affect our <font color="blue">relationships</font> outside of those areas</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>     you that as a result of this <font color="blue">reallocation</font> our <font color="blue">losses will decrease</font> or we     will achieve any <font color="blue">particular patient count</font> or <font color="blue">revenue level</font></td>
    </tr>
    <tr>
      <td>Our patient     count and <font color="blue">revenue level</font> may decline in the near term due to attrition in     <font color="blue">areas outside</font> of our <font color="blue">PHD Operating Districts</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock       Our <font color="blue">common stock</font> has been <font color="blue">delisted from</font> the <font color="blue">Nasdaq National Market </font>and could     be <font color="blue">delisted from</font> <font color="blue">the <font color="blue">Nasdaq Capital Market</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">On November </font>14, 2005, we received a <font color="blue">letter from</font> the Nasdaq noting that we     had failed to <font color="blue">comply with</font> the minimum dlra10 million of <font color="blue">stockholders</font>’ equity     required  by  <font color="blue">Marketplace Rule </font>4450(a), <font color="blue">Maintenance Standard </font>1 and the     <font color="blue">alternative</font> listing <font color="blue">requirement</font>s of <font color="blue">Marketplace Rule </font>4450(b), Maintenance     Standard 2 relating to <font color="blue">market value</font> of <font color="blue">listed securities</font> (and related assets     and <font color="blue">revenue tests</font>) and <font color="blue">market value</font> of publicly held shares</td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>16,     2005,  we were <font color="blue">notified by</font> the Nasdaq that for the last 30 consecutive     business days the bid price of our <font color="blue">common stock</font> has closed below the minimum     dlra1dtta00 per share required by <font color="blue">Marketplace Rule </font>4450(a)(5)</td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>27,     2005, we received a <font color="blue">letter from</font> the       31     ______________________________________________________________________       Nasdaq denying our request for <font color="blue"><font color="blue">continued listing</font> on</font> the Nasdaq National     Market</td>
    </tr>
    <tr>
      <td>In response to this letter, on <font color="blue">December </font>30, 2005, we requested a     hearing before the <font color="blue">Nasdaq Listing Qualifications Panel </font>to review <font color="blue">the Nasdaq     </font>staff’s determination</td>
    </tr>
    <tr>
      <td>We <font color="blue">subsequently</font> received <font color="blue">notification from</font> <font color="blue">the Nasdaq     </font>Listing Qualifications Panel that our <font color="blue">common stock</font> would be <font color="blue">delisted from</font>     the <font color="blue">Nasdaq National Market </font>and would begin trading on the Nasdaq Capital     Market on <font color="blue">February </font>14, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">Nasdaq Capital Market</font> </font>has its own standards for <font color="blue">continued listing</font>,     including  <font color="blue">Marketplace Rule </font>4310(c)(2)(B), which requires us to have a     minimum of dlra2cmam500cmam000 in <font color="blue">stockholders</font>’ equity or dlra35cmam000cmam000 <font color="blue">market value</font> of     <font color="blue">listed securities</font> or dlra500cmam000 of net income from continuing <font color="blue">operations</font> for     the <font color="blue">most recently</font> completed <font color="blue">fiscal year</font> or two of the three <font color="blue">most recently</font>     completed <font color="blue">fiscal year</font>s</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue"><font color="blue">continued listing</font> on</font> the Nasdaq Capital     Market requires satisfying the dlra1dtta00 minimum closing <font color="blue">bid price imposed by</font>     <font color="blue">Marketplace Rule </font>4450(a)(5)</td>
    </tr>
    <tr>
      <td>There can be no assurance that we <font color="blue">will sustain</font>     <font color="blue">compliance with</font> these standards</td>
    </tr>
    <tr>
      <td>In particular, we do not currently have a     minimum of dlra2cmam500cmam000 in <font color="blue">stockholders</font>’ equity and we did not have dlra500cmam000     of net income from continuing <font color="blue">operations</font> for the <font color="blue">most recently</font> completed     <font color="blue">fiscal year</font> or two of the three <font color="blue">most recently</font> completed <font color="blue">fiscal year</font>s, but     the current <font color="blue">market value</font> of our <font color="blue">listed securities</font> does exceed dlra35cmam000cmam000</td>
    </tr>
    <tr>
      <td>In the event we cannot sustain <font color="blue">compliance with</font> <font color="blue">the <font color="blue">Nasdaq Capital Market</font></font>’s     listing standards, our <font color="blue">common stock</font> will be <font color="blue">delisted from</font> the Nasdaq Capital     Market  and we may be unable to list our <font color="blue">common stock</font> on another stock     exchange or quotation service</td>
    </tr>
    <tr>
      <td>Such a delisting may make it <font color="blue">difficult</font> or     impossible for <font color="blue">stockholders</font> to sell their shares, for us to issue <font color="blue">additional</font>     securities  and for us to obtain <font color="blue">additional</font> financing in the future</td>
    </tr>
    <tr>
      <td>A     <font color="blue">delisting may also</font> result in a more limited amount of news and analyst     coverage for our Company and could have a material adverse effect on the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> becomes a “<font color="blue">penny stock</font>” you may find it <font color="blue">difficult</font> to     <font color="blue">resell shares</font></td>
    </tr>
    <tr>
      <td>Generally,  a  “<font color="blue">penny stock</font>” is a <font color="blue">common stock</font> that is not listed on a     securities exchange and trades for less than dlra5dtta00 a share</td>
    </tr>
    <tr>
      <td>Prices often are     not available to buyers and sellers and the <font color="blue">market may</font> be very limited</td>
    </tr>
    <tr>
      <td>Penny  stocks  in  start-up  companies  are  among the <font color="blue">riskiest equity</font>     <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>Broker-dealers who sell <font color="blue">penny stock</font>s must provide purchasers of     these stocks with a <font color="blue">standardized</font> risk-disclosure document prepared by the     <font color="blue"><font color="blue">Securities </font>and Exchange Commission</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">document provides</font> information about     <font color="blue">penny stock</font>s and the nature and level of <font color="blue">risks involved</font> in investing in the     penny  <font color="blue">stock market</font></td>
    </tr>
    <tr>
      <td>A broker must also give a purchaser, orally or in     writing, bid and <font color="blue">offer quotations</font> and information regarding broker and     <font color="blue">salesperson compensation</font>, make a <font color="blue">written determination</font> that the <font color="blue">penny stock</font>     is a suitable <font color="blue">investment</font> for the purchaser, and obtain the purchaser’s     written <font color="blue">agreement</font> to the purchase</td>
    </tr>
    <tr>
      <td>Many <font color="blue">brokers choose</font> not to <font color="blue">participate</font> in     <font color="blue">penny stock</font> <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> is <font color="blue">delisted from</font> <font color="blue">the Nasdaq     </font>Capital Market and we are unable to satisfy certain other financial tests we     will  be  classified  as a “<font color="blue">penny stock</font>” as that term is defined under     Rule 3a51-1 of the <font color="blue"><font color="blue">Securities </font>Exchange Act </font>of 1934</td>
    </tr>
    <tr>
      <td>Because of the penny     stock rules, there is <font color="blue">less trading activity</font> in <font color="blue">penny stock</font>, and <font color="blue">consequently</font>     you may have <font color="blue">difficult</font>y selling your shares</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is <font color="blue">thinly traded</font>, so you may be unable to sell at or near     ask price or at all if you need to liquidate your shares</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common shares</font> have <font color="blue">historically been sporadically</font> or “thinly-traded” on     <font color="blue">the <font color="blue">Nasdaq Capital Market</font></font> and the <font color="blue">Nasdaq National Market </font>(prior to our     <font color="blue">delisting from</font>  the Nasdaq National Market), meaning that the number of     <font color="blue">persons interested</font> in purchasing our <font color="blue">common shares</font> at or near <font color="blue">ask prices at</font>     any given time may be <font color="blue">relatively</font> small or non-existent</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31,     2005, our <font color="blue">average trading volume per day</font> for the <font color="blue">past three months</font> was     <font color="blue">approximately</font> 57cmam932 shares a day with a high of 425cmam322 shares traded and a     low of 1cmam775 shares traded</td>
    </tr>
    <tr>
      <td>This situation is <font color="blue">attributable</font> to a number of     factors, including the fact that we are a small <font color="blue">company which</font> is <font color="blue">relatively</font>     unknown to stock analysts, stock brokers, institutional investors and others     in the <font color="blue">investment</font> community that generate or <font color="blue">influence sales volume</font>, and       32     ______________________________________________________________________       that even if we came to the attention of <font color="blue">such persons</font>, they tend to be     risk-averse and would be reluctant to follow an <font color="blue">unproven company such as</font>     ours or purchase or recommend the purchase of our <font color="blue">shares until such</font> time as     we became more seasoned and viable</td>
    </tr>
    <tr>
      <td>As a consequence, there may be periods     of several days or more when trading activity in our shares is low, as     compared to a <font color="blue">seasoned issuer which</font> has a large and <font color="blue">steady volume</font> of trading     activity that <font color="blue">will <font color="blue">generally</font> support continuous sales without</font> an adverse     effect on share price</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot give</font> you any assurance that a broader or     more <font color="blue">active public trading market</font> for our <font color="blue">common shares</font> will develop or be     sustained, or that <font color="blue">current trading levels will</font> be sustained</td>
    </tr>
    <tr>
      <td>The  market  price  of  our <font color="blue">common stock</font> may be subject to <font color="blue">significant</font>     <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> may fluctuate widely depending upon many     factors, including our perceived prospects and those of the <font color="blue">dialysis market</font>     in general</td>
    </tr>
    <tr>
      <td>Since our <font color="blue">initial public offering</font> in May 1996, our <font color="blue">common stock</font>     price has traded between dlra0dtta52 and dlra23dtta50 per share and we have <font color="blue">generally</font>     experienced <font color="blue">relatively</font> low trading volume in relation to the aggregate     number of <font color="blue">shares outstanding</font></td>
    </tr>
    <tr>
      <td>Factors that may have a <font color="blue">significant</font> impact on the <font color="blue">market price</font> or liquidity     of our <font color="blue">common stock</font> include:       ·       reports by official or <font color="blue">unofficial health</font> or <font color="blue">medical authorities</font>, the     <font color="blue">general media</font> or the FDA regarding the <font color="blue">potential benefits</font> or <font color="blue">detriments</font> of     our PHD System or of similar <font color="blue">products distributed by</font> other companies, or of     daily or <font color="blue">home dialysis</font>;       ·       <font color="blue">announcements</font> of <font color="blue">technological</font> innovations or <font color="blue">new products by us</font> or     our <font color="blue"><font color="blue">competitor</font>s</font>;       ·       events or <font color="blue">announcements</font> relating to our <font color="blue">relationships</font> with others,     including our <font color="blue">third party</font> <font color="blue">manufacture</font>rs;       ·       <font color="blue">development</font>s or <font color="blue">disputes concerning patents</font> or <font color="blue">proprietary</font> rights;       ·        regulatory <font color="blue">development</font>s in both the <font color="blue"><font color="blue">United States</font> </font>and foreign     countries;       ·       economic and other factors, as well as period-to-period fluctuations     in our financial results; and       ·       sales of our <font color="blue">common stock</font> by <font color="blue">the Durus </font>fund</td>
    </tr>
    <tr>
      <td>External <font color="blue">factors may</font> also <font color="blue">adversely</font> affect the <font color="blue">market price</font> for the common     stock</td>
    </tr>
    <tr>
      <td>The <font color="blue">common stock</font> currently trades on <font color="blue">the <font color="blue">Nasdaq Capital Market</font></font></td>
    </tr>
    <tr>
      <td>The     price and liquidity of the <font color="blue">common stock</font> may be <font color="blue">significant</font>ly affected by the     <font color="blue">overall trading activity</font> and market factors on <font color="blue">the <font color="blue">Nasdaq Capital Market</font></font> or     the market, if any, on which we are then trading</td>
    </tr>
    <tr>
      <td>Future sales of substantial amounts of our <font color="blue">common stock</font> in the <font color="blue">public market</font>     could <font color="blue">adversely</font> affect the <font color="blue">market price</font> of the <font color="blue">common stock</font>, and also could     impair our ability to raise <font color="blue">additional</font> capital through the sale of our     <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>The resale by <font color="blue">the Durus </font>fund of a substantial number of shares of our common     stock could <font color="blue">adversely</font> impact the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Based on information contained in a Schedule 13D filed by <font color="blue">the Durus </font>fund     with the <font color="blue"><font color="blue">Securities </font>and Exchange Commission</font> on March 13, 2006, we believe     <font color="blue">the Durus </font>fund owns 21cmam498cmam118 shares of our <font color="blue">common stock</font>, representing     <font color="blue">approximately</font> 66prca of our <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>We have filed a <font color="blue">registration</font>     <font color="blue">statement covering</font> these shares and 498cmam100 shares held by the Artal fund</td>
    </tr>
    <tr>
      <td>This <font color="blue">registration</font> statement was declared <font color="blue">effective</font> by the <font color="blue">Securities </font>and     <font color="blue">Exchange Commission </font>on May 17, 2004, and enables <font color="blue">the Durus </font>fund and the     Artal  fund  to resell their shares to the public at their <font color="blue">discretion</font></td>
    </tr>
    <tr>
      <td>Although we believe that <font color="blue">the Durus </font>fund and the Artal <font color="blue">fund will effectuate</font>     the sale of their shares in an <font color="blue">orderly manner</font> and will seek to obtain the     <font color="blue">best prices available</font> in <font color="blue">connection with</font> any sales, the timing, volume and     manner of any sales is within their <font color="blue">discretion</font></td>
    </tr>
    <tr>
      <td>33     ______________________________________________________________________       <font color="blue">The Durus </font>fund and the Artal fund’s sale of their <font color="blue">shares may</font> have a negative     effect on the <font color="blue">market price</font> of our <font color="blue">common stock</font> due to, among other factors,     the <font color="blue">selling pressure such sales may</font> cause</td>
    </tr>
    <tr>
      <td>Moreover, the <font color="blue">perception</font> in the     market that a <font color="blue">significant</font> portion of our <font color="blue">outstanding shares</font> may soon be sold     may also have a negative effect on the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">events may</font> cause other holders of our <font color="blue">common stock</font> to sell their     shares, or it <font color="blue">may encourage</font> short sales, all of <font color="blue">which could contribute</font> to a     decline in the <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">factors may</font>     have a material adverse effect on our ability to <font color="blue">raise capital through</font> the     issuance of our <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>We  do  not  intend  to  <font color="blue">pay <font color="blue"><font color="blue">cash dividends</font> on</font></font> our <font color="blue">common stock</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have never declared or paid any <font color="blue"><font color="blue">cash dividends</font> on</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For     the <font color="blue">foreseeable future</font>, we intend to retain any earnings to finance the     <font color="blue">development</font>  of our business, and we do not anticipate paying any cash     dividends on our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Payment of any <font color="blue">future dividends on</font> our common     <font color="blue">stock will depend upon</font> our earnings and capital <font color="blue">requirement</font>s, the terms of     any <font color="blue">indebtedness</font> we incur and other factors our board of <font color="blue">directors</font> considers     <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will likely</font> need to issue <font color="blue">additional</font> shares of our <font color="blue">common stock</font> and/or     <font color="blue">preferred stock</font> in the future, <font color="blue">which would dilute</font> your voting and ownership     percentage</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">events over which</font> you have <font color="blue">no control could</font> result in the issuance     of <font color="blue">additional</font> shares of our <font color="blue">common stock</font>, <font color="blue">which would dilute</font> your voting and     ownership  interest  in  our Company</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>20, 2006, there were     32cmam177cmam574 shares of our <font color="blue">common stock</font> issued and outstanding and there were     717cmam677  shares of <font color="blue">common stock</font> reserved for <font color="blue">issuance under</font> our equity     incentive  and  <font color="blue">stock purchase</font> plans</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>20, 2006, there were     outstanding  options,  warrants  and  other  rights  to  acquire up to     <font color="blue">approximately</font> 3cmam338cmam602 shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We may also issue <font color="blue">additional</font>     shares of <font color="blue">common stock</font> or <font color="blue">preferred stock</font>:       ·        to  raise  <font color="blue">additional</font> funds for working capital, research and     <font color="blue">development</font>, <font color="blue">commercialization</font>, production and <font color="blue">marketing activities</font>;       ·       upon the exercise or <font color="blue">conversion</font> of <font color="blue">outstanding options</font> and warrants;     and       ·       in lieu of payment of <font color="blue">cash dividends</font></td>
    </tr>
    <tr>
      <td><font color="blue">Furthermore </font>upon closing of our securities purchase <font color="blue">agreement</font> with <font color="blue">the Durus </font>    fund dated March 31, 2006 (the “<font color="blue">Securities </font>Purchase Agreement”) , <font color="blue">the Durus </font>    fund will acquire <font color="blue">newly issued shares</font> of our Series B Preferred Stock,     convertible into 5 million shares of our <font color="blue">common stock</font> at a <font color="blue">conversion</font> price     of dlra1dtta00 per share and Warrants to purchase 5 million shares of our common     stock at an <font color="blue">exercise price</font> of dlra1dtta10 per share</td>
    </tr>
    <tr>
      <td>In addition, following the     closing of the <font color="blue">Securities </font>Purchase Agreement, <font color="blue">the Durus </font>fund will have the     option to invest, by itself or with other <font color="blue">investors designated by</font> <font color="blue">the Durus </font>    fund, up to an <font color="blue">additional</font> dlra15 million in cash for <font color="blue">additional</font> shares of     <font color="blue">Series B Preferred Stock and Warrants </font>having <font color="blue">essentially</font> the <font color="blue">same terms as</font>     the <font color="blue">Series B Preferred Stock and Warrants </font>acquired by <font color="blue">the Durus </font>fund at the     closing</td>
    </tr>
    <tr>
      <td>If <font color="blue">the Durus </font>fund (by itself or with other investors) invests the     maximum  <font color="blue">additional</font>  dlra15 million in cash for such <font color="blue">additional</font> shares of     Series B Preferred Stock and Warrants, such <font color="blue">additional</font> shares of Series B     Preferred Stock will be convertible into 15 million shares of <font color="blue">common stock</font>     at a <font color="blue">conversion</font> price of dlra1dtta00 per Share and the <font color="blue">additional</font> Warrants will be     exercisable to purchase 15 million shares of <font color="blue">common stock</font> at an exercise     price of dlra1dtta10 per share</td>
    </tr>
    <tr>
      <td>See “Management’s Discussion and Analysis of     Financial  Condition  and  Results of Operations—Liquidity and Capital     Resources—Recent Financing Activities</td>
    </tr>
    <tr>
      <td>” See also “Risks Related to Our     Business—As a result of our <font color="blue">transaction</font> with <font color="blue">the Durus </font>fund and <font color="blue">the Durus </font>    fund’s <font color="blue">current ownership position</font> in our common and <font color="blue">preferred stock</font>, persons     other than <font color="blue">the Durus </font>fund who own our <font color="blue">common stock</font> will own a minority of     our <font color="blue">common stock</font> and will not be able to <font color="blue">exercise <font color="blue">voting control</font> over most</font>     <font color="blue">matters put</font> to a vote of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>”       34     ______________________________________________________________________       Our  charter  <font color="blue">documents</font> and Section 203 of the DGCL could make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us</td>
    </tr>
    <tr>
      <td>Our  Restated Certificate of In<font color="blue">corporation</font> (“Charter”) and Amended and     Restated Bylaws (“Bylaws”) <font color="blue">contain certain provisions</font> that are intended to     enhance the likelihood of <font color="blue">continuity</font> and stability in the <font color="blue">composition</font> of our     board of <font color="blue">directors</font> and which may have the effect of delaying, deferring or     preventing a <font color="blue">future takeover</font> or change in control of the Company unless the     takeover or change of control is <font color="blue">approved by</font> our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">provisions may also</font> render the removal of the <font color="blue">current board</font> of <font color="blue">directors</font> and     of <font color="blue">management</font> more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions provide</font> for, among other     things:       ·       a <font color="blue">classified board</font> of <font color="blue">directors</font>;       ·       “fair price” provision, which requires that our <font color="blue">stockholders</font> receive     <font color="blue">equivalent consideration at both stages</font> of a two-step <font color="blue">acquisition</font> (such as a     <font color="blue">tender offer followed by</font> a merger);       ·       a prohibition on stockholder action through written consents;       ·       a <font color="blue">requirement</font> that <font color="blue"><font color="blue">special meeting</font>s</font> of <font color="blue">stockholders</font> be <font color="blue">called only</font>     by our board of <font color="blue">directors</font> or our <font color="blue">chief executive officer</font>;       ·        advance  notice  <font color="blue">requirement</font>s  for  <font color="blue">stockholder proposals</font> and     <font color="blue">nominations</font>;       ·       <font color="blue">limitations</font> on the ability of <font color="blue">stockholders</font> to amend, alter or repeal     our Charter or our Bylaws; and       ·        the  authority  of  our  board of <font color="blue">directors</font> to issue, without     stockholder  approval, <font color="blue">preferred stock</font> with such terms as the board of     <font color="blue">directors</font> may determine</td>
    </tr>
    <tr>
      <td>We  are  subject  to the “business <font color="blue">combination</font>” statute of the General     Corporation  Law  of  the  State of <font color="blue">Delaware </font>(the “DGCL”)</td>
    </tr>
    <tr>
      <td>In general,     Section 203 of the DGCL prohibits a publicly-held <font color="blue">Delaware </font><font color="blue">corporation</font> from     engaging in a “business <font color="blue">combination</font>” with an “<font color="blue">interested stockholder</font>,” for a     period of <font color="blue">three years</font> after the date of the <font color="blue">transaction</font> in which a person     became an “<font color="blue">interested stockholder</font>,” unless:       ·        prior  to such date the board of <font color="blue">directors</font> of the <font color="blue">corporation</font>     approved either the “business <font color="blue">combination</font>” or the <font color="blue">transaction</font> which resulted     in the <font color="blue">stockholder becoming</font> an “<font color="blue">interested stockholder</font>,”       ·        upon  <font color="blue">consummation</font>  of  the <font color="blue">transaction</font> which resulted in the     stockholder  becoming  an  “interested  stockholder,”  the “interested     stockholder”  owns at least 85prca of the <font color="blue">voting stock</font> of the <font color="blue">corporation</font>     outstanding at the time the <font color="blue">transaction</font> commenced, excluding for purposes of     determining the number of <font color="blue">shares outstanding</font> those shares owned (1) by     persons who are <font color="blue">directors</font> and <font color="blue">also officers</font> and (2) employee stock plans in     which  employee  <font color="blue">participants</font>  do  not  have  the  right  to determine     <font color="blue">confidential</font>ly whether shares held subject to the plan will be tendered in a     tender or <font color="blue">exchange offer</font>, or       ·       on or subsequent to such date the “business <font color="blue">combination</font>” is approved     by the board of <font color="blue">directors</font> and <font color="blue">authorized at</font> an annual or <font color="blue">special meeting</font> of     <font color="blue">stockholders</font> by the <font color="blue">affirmative vote</font> of at least 662¤3prca of the outstanding     <font color="blue">voting stock</font>, which is not owned by the “<font color="blue">interested stockholder</font></td>
    </tr>
    <tr>
      <td>”       A “business <font color="blue">combination</font>” includes mergers, stock or <font color="blue">asset sales</font> and other     <font color="blue">transaction</font>s  resulting  in  a  financial  benefit  to the “interested     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>”  An “<font color="blue">interested stockholder</font>” is a person who, <font color="blue">together with</font>     <font color="blue">affiliates</font> and <font color="blue">associates</font>, owns (or within <font color="blue">three years</font>, did own) 15prca or more     of the <font color="blue">voting stock</font> of the subject <font color="blue">corporation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although Section </font>203 permits     us to elect not to be <font color="blue">governed by</font> its provisions, we have not made this     election</td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">application</font> of Section 203, potential acquirers     of our <font color="blue">company may</font> be <font color="blue">discouraged from attempting</font> to effect an <font color="blue">acquisition</font>     <font color="blue">transaction</font> with us, thereby possibly depriving holders of our securities of     certain <font color="blue">opportunities</font> to sell or <font color="blue">otherwise dispose</font> of <font color="blue">such securities at</font>     above-<font color="blue">market price</font>s pursuant to such <font color="blue">transaction</font>s</td>
    </tr>
    <tr>
      <td>35     ______________________________________________________________________       The <font color="blue">foregoing summaries</font> do not purport to be complete and are subject to,     and are qualified in their entirety by reference to, our Charter and Bylaws,     our Rights Agreement and the DGCL Copies of our Charter and  Bylaws are     <font color="blue">filed as exhibits</font> to this report and deemed to be <font color="blue">incorporated herein</font> in     their entirety</td>
    </tr>
    <tr>
      <td>If we sell <font color="blue">common stock</font> to <font color="blue">Fusion Capital </font>under our <font color="blue">common stock</font> purchase     <font color="blue">agreement</font> with them you <font color="blue">will likely</font> experience <font color="blue">significant</font> dilution and the     resale of shares of <font color="blue">common stock</font> acquired by <font color="blue">Fusion Capital </font>could cause the     price of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>The sale of <font color="blue">shares pursuant</font> to our <font color="blue">common stock</font> purchase <font color="blue">agreement</font> with     <font color="blue">Fusion Capital </font>or any other <font color="blue">future equity financing</font> <font color="blue">transaction</font> will have a     <font color="blue">dilutive impact on</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As a result, our net income or loss per     share could decrease in future periods, and the <font color="blue">market price</font> of our common     <font color="blue">stock could decline</font></td>
    </tr>
    <tr>
      <td>In addition, the lower our stock price is, the more     shares of <font color="blue">common stock</font> we will have to <font color="blue">issue under</font> the <font color="blue">common stock</font> purchase     <font color="blue">agreement</font>  with  Fusion  Capital in order to draw down the full amount     available to us on any trading day</td>
    </tr>
    <tr>
      <td>If our stock price were lower, then our     existing <font color="blue">stockholders</font> would experience <font color="blue">greater dilution</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font>     the actual number of shares of <font color="blue">common stock</font> that will be <font color="blue">issued pursuant</font> to     the <font color="blue">agreement</font> with <font color="blue">Fusion Capital </font>or any other <font color="blue">future equity financing</font>     <font color="blue">transaction</font>,  in  part,  because the <font color="blue">purchase price</font> of the <font color="blue">shares will</font>     fluctuate <font color="blue">based on</font> prevailing market conditions and we do not know the exact     amount of funds we will need</td>
    </tr>
    <tr>
      <td>The <font color="blue">purchase price</font> for the <font color="blue">common stock</font> to be     sold to <font color="blue">Fusion Capital </font>pursuant to the <font color="blue">common stock</font> purchase <font color="blue">agreement</font> will     fluctuate <font color="blue">based on</font> the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fusion Capital </font>may sell     none, some or all of the shares of <font color="blue">common stock</font> purchased from us at any     time</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font><font color="blue">upon market liquidity at</font> the time, a sale of <font color="blue">shares by</font>     <font color="blue">Fusion Capital </font>at any given time could cause the <font color="blue">trading price</font> of our common     stock to decline</td>
    </tr>
    <tr>
      <td>The sale of a substantial number of shares of our common     stock by Fusion Capital, or <font color="blue">anticipation</font> of such sales, could make it more     <font color="blue">difficult</font> for us to sell equity or equity-related securities in the future     at a time and at a price that we <font color="blue">might otherwise</font> wish to effect sales</td>
    </tr>
    <tr>
      <td>See     also  “Risks  Related to Our Common Stock—we <font color="blue">will likely</font> need to issue     <font color="blue">additional</font> shares of our <font color="blue">common stock</font> and/or <font color="blue">preferred stock</font> in the future,     <font color="blue">which would dilute</font> your voting and <font color="blue">ownership percentage</font></td>
    </tr>
  </tbody>
</table>